REVTORPYK (gedatolisib) plus fulvestrant approved for HR+/HER2−, PIK3CA wild-type advanced breast cancer (Jul 14 2026).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/20/26) through T+1. Run-up high $144.98 on 5/4/26, low $87.32 on 6/16/26 (T-120 to T-1). FDA decision 7/14/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-07-14
OutcomeApproved
Drug / candidateGedatolisib with Fulvestrant - (VIKTORIA-1)
IndicationHR+/HER2− advanced breast cancer (PIK3CA wild-type)
CompanyCelcuity Inc.
Market-cap tierMid
120-day run-up (T-120→T-1)-1.5%
Cohort decision-day move (history)2.1% median (n=230)
The PDUFA goal date was July 17, 2026; the FDA approved on July 14, 2026, three days early. This page previously carried another company's chart, indication and dates through a template-copy bug; it was rebuilt from Celcuity's own price history on July 15, 2026. See /corrections.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.